455264-29-6

Usage

Uses

Used in Pharmaceutical Industry:
(S)-ethyl 3-(4-(2,7-naphthyridin-1-ylamino)phenyl)-2-(3-oxospiro[3.5]non-1-en-1-ylamino)propanoate is used as a potential candidate for the development of new drugs or therapeutic agents due to its unique molecular structure and the presence of biologically active components such as an amino group and a spiro ring.
Further research and analysis are required to fully understand the compound's potential uses, effects, and its role in the pharmaceutical industry. (S)-ethyl 3-(4-(2,7-naphthyridin-1-ylaMino)phenyl)-2-(3-oxospiro[3.5]non-1-en-1-ylaMino)propanoate's chiral nature may also offer opportunities for targeted drug design, where one enantiomer could have desired therapeutic effects while the other may not, allowing for more precise and effective treatments.

Upstream product

• 15546-27-7 1-keto-3-hydroxyspiro[3.5]-non-2-ene 
• 369648-61-3 ethyl-(2S)-2-amino-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoate 
• 69042-30-4 1-chloro-[2,7]naphthyridine 
• 644995-09-5 (S)-3-(4-amino-phenyl)-2-(3-oxo-spiro[3.5]non-1-en-1-ylamino)-propionic acid ethyl ester 

Downstream Products

• 455264-30-9 zaurategrast ethyl 
• 1214745-94-4 UC⁽⁹¹¹⁾B₁₁₃₃ 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF PHENYLALANINE ENAMIDE DERIVATIVES

A process for the preparation of a class of phenylalanine enamide derivatives is described formula (1) wherein: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a linker group selected from -N(R4)- [where R4 is a hydrogen atom or an optionally substituted straight or branched C1-6alkyl group], -CON(R4)-, or -S(O)2N(R4)-; R1 is a carboxylic acid (-CO2H) or a derivative or biostere thereof; R2 is a hydrogen atom or a C1-6alkyl group; Rx, Ry and Rz which may be the same or different is each an atom or group -L1(Alk1)n(R3)v; and the salts, solvates, hydrates and N-oxides thereof; which comprises reacting a compound of formula (2): wherein: Qa is a group -N(R4)H; and the salts, solvates, hydrates and N-oxides thereof; with a compound Ar1W wherein W is a group selected from X1 (wherein X1 is a leaving atom or group), -COX2 (wherein X2 is a halogen atom or a -OH group) or -SO2 X3 (in which X3 is a halogen atom).

PHENYLALANINE ENAMIDE DERIVATIVES

Phenylalanine enamide derivatives of formula (1) are described, wherein R1is a -CH(CH3)2, -(CH2)2CH3; -CH2C(CH3)3, -CH2CH2OH, -CH2CH2OCH3, -CH2CH2OCH2CH2OH, -CH2CH2OCH2CH2OCH3, formula (A) group; and the salts, solvates and N-oxides thereof. Compounds according to the invention are potent and selective inhibitors of α4 integrins. The compounds are of use in modulating cell adhesion and in particular are of use in the prophylaxis and treatment of diseases or disorders including inflammation in which the extravasation of leukocytes plays a role and the invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such diseases or disorders.

Phenylalanine enamide derivatives

Phenylalanine enamide derivatives of formula (1) are described: wherein R1 is a group Ar1L2Ar2Alk- in which: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a covalent bond or a linker atom or group; Ar2 is an optionally substituted arylene or heteroarylene group; and Alk is a chain —CH2—CH(R)13 , —CH═C(R)— or ?in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof; X is an —O— or —S— atom or —N(R2)— group in which: Rx, Ry and Rz which may be the same or different is each a hydrogen atom or an optional substituent; or Rz is an atom or group as previously defined and Rx and Ry are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.